

Tarlatamab DeLLphi-301

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Tarlatamab DeLLphi-301

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: Tarlatamab treatment for the extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (10mg)
Experimental Arm: Tarlatamab
Control Arm: Single arm



